Phase III
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Roche announced topline data from two identical Phase III trials, TENAYA and LUCERNE, of faricimab in neovascular or “wet” age-related macular degeneration (nAMD).
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.
Protecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial.
The decision was made based on an Independent Data Monitoring Committee recommendation which indicated the study was unlikely to meet its specified primary efficacy endpoint of progression-free survival.
VP-102, which has the potential to be the first product approved by the FDA for the treatment of molluscum contagiosum, contains a GMP-controlled formulation of cantharidin (0.7% w/v), which is delivered via a single-use applicator that allows for precise topic dosing and targeted administration.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
Being studied for GAD, OCD, AD and spinocerebellar ataxia, Biohaven’s troriluzole has now struck out in 3 late-stage studies.
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
PRESS RELEASES